Publications

@article{nokey,

title = {Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile},

author = {Myriam El Gaaloul and Andre Marie Tchouatieu and Kassoum Kayentao and Brice Campo and Benedicte Buffet and Hanu Ramachandruni and Jean Louis Ndiaye and Timothy N. C. Wells and Celine Audibert and Jane Achan and Cristina Donini and Hellen C. Barsosio and Halidou Tinto},

url = {https://pubmed.ncbi.nlm.nih.gov/39425110/},

doi = {10.1186/S12936-024-05128-1},

issn = {1475-2875},

year  = {2024},

date = {2024-01-01},

journal = {Malaria journal},

volume = {23},

issue = {1},

pages = {315},

publisher = {Malar J},

abstract = {\<p\>Malaria is preventable, but the burden of disease remains high with over 249 million cases and 608,000 deaths reported in 2022. Historically, the most important protective interventions have been vector control and chemopreventive medicines with over 50 million children receiving seasonal malaria chemoprevention in the year 2023. Two vaccines are approved and starting to be deployed, bringing additional protection for children up to 36 months. However, the impact of these currently available tools is somewhat limited on various fronts. Vaccines exhibit partial efficacy, are relatively costly, and not accessible in all settings. The challenges encountered with chemoprevention are barriers to acceptability and feasibility, including frequency of dosing, and the lack of options in the first trimester of pregnancy and for women living with HIV. Also, the emergence of resistance against chemopreventive medicines is concerning. To address these limitations, a target product profile (TPP) is proposed as a road map to guide innovation and to boost the quest for novel chemopreventive alternatives. This TPP describes the ideal product attributes, while acknowledging potential trade-offs that may be needed. Critically, it considers the target populations most at risk; primarily infants, children, and pregnant women. Malaria control and elimination requires appropriate chemoprevention, not only in areas of high endemicity and transmission, but also in lower transmission areas where immunity is declining, as well as for travellers from areas where malaria has been eliminated. New medicines should show acceptable safety and tolerability, with high and long protective efficacy. Formulations and costs need to support operational adherence, access, and effectiveness. Next generation long-acting oral and injectable drugs are likely to constitute the backbone of malaria prevention. Therefore, the perspectives of front-line experts in malaria prevention, researchers, and those involved in drug development are captured in the TPP. This inclusive approach aims at concentrating efforts and aligning responses across the community to develop new and transformative medicines.\</p\>},

keywords = {Administration, Andre Marie Tchouatieu, Antimalarials* / administration \& dosage, Antimalarials* / therapeutic use, Chemoprevention* / methods, doi:10.1186/s12936-024-05128-1, Female, Halidou Tinto, Humans, Injections, Malaria* / prevention \& control, MEDLINE, Myriam El Gaaloul, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, Oral, PMC11490162, pmid:39425110, Pregnancy, PubMed Abstract, Review},

pubstate = {published},

tppubtype = {article}

}

@article{Yerbanga2023,

title = {Performances of disk diffusion method for determining triazole susceptibility of Aspergillus species: Systematic review},

author = {Isidore W. Yerbanga and Seydou Nakanabo Diallo and Toussaint Rouamba and Agustin Resendiz-Sharpe and Katrien Lagrou and Olivier Denis and Hector Rodriguez-Villalobos and Isabel Montesinos and Sanata Bamba},

url = {https://pubmed.ncbi.nlm.nih.gov/37603962/},

doi = {10.1016/J.MYCMED.2023.101413},

issn = {1773-0449},

year  = {2023},

date = {2023-01-01},

journal = {Journal de mycologie medicale},

volume = {33},

issue = {4},

publisher = {J Mycol Med},

abstract = {The therapeutic management of invasive aspergillosis should be guided by antifungal susceptibility testing (AFST). The disk diffusion (DD) method due to its simplicity and low cost could be an appropriate alternative to the reference methods (CLSI, EUCAST) which are not suitable for AFST in routine clinical microbiology laboratories, particularly in resource-constrained settings. This review summarizes the available data on the performance of the DD method in determining triazole susceptibility profile of Aspergillus species. The published articles on the performance of DD method for determining triazole susceptibility of Aspergillus spp. were systematically searched on major medical databases and Google Scholar. We identified 2725 articles of which 13 met the inclusion criteria. The overall average agreement value obtained between DD and CLSI broth microdilution (CLSI-BMD) methods for the itraconazole 10 µg disk (70.75%) was low especially when the medium used was not Mueller-Hinton (MH) agar. In contrast average agreement for the voriconazole 1 µg disk and the posaconazole 5 µg disk were \> 94% regardless of media used. The correlation coefficient values between the DD and CLSI-BMD methods on MH agar were acceptable (≥ 0.71) for the itraconazole 10 µg disk and posaconazole 5 µg disk and good (≥ 0.80) for the voriconazole 1 and 10 µg disk. The reproducibility of the DD method regardless to the medium used was ≥ 82%. This systematic review shows that the disk diffusion method could be a real alternative for triazole antifungals susceptibility testing of Aspergillus spp.},

keywords = {Agar, Antifungal Agents* / pharmacology, Aspergillus, doi:10.1016/j.mycmed.2023.101413, Isidore W Yerbanga, Itraconazole* / pharmacology, MEDLINE, Microbial Sensitivity Tests, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, pmid:37603962, PubMed Abstract, Reproducibility of Results, Review, Sanata Bamba, Seydou Nakanabo Diallo, Systematic review, Triazoles / pharmacology, Voriconazole / pharmacology},

pubstate = {published},

tppubtype = {article}

}